Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.51 |
| ▸ | CTSC | P53634 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5600734 | 1.00 | CCR3 (0.56) | CCR3CYP3A4TSHRALPIPKM | |
| SCHEMBL9113781 | 0.92 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL11254327 | 0.92 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL18375234 | 0.92 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL16559587 | 0.90 | ALPI (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2310422 | 0.90 | CYP3A4 (0.67) | CYP3A4TSHRALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL2927527 | 0.90 | ALPI (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2310428 | 0.90 | CYP3A4 (0.67) | CYP3A4TSHRALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL15467518 | 0.89 | CYP3A4 (0.65) | CYP3A4TSHRALPIPKMPTGS1 | |
| SCHEMBL21010316 | 0.89 | SLC15A1 (0.64) | CYP3A4TSHRALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273856-B2 | Linear basic compounds having NK-2 antagonist activity and formulations thereof | MENARINI RICERCHE S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| EP-1442050-B1 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI SAS (IT) | 2006-09-13 | — | — | EP | disclosed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | disclosed |
| EP-1442050-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.p.A. (IT) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037916-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | CCR3 1653/4885CYP3A4 2699/4885TSHR 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.